Stay updated with breaking news from Ted Raad. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
By Ben Glickman Pulmatrix will close a study of a potential treatment for a fungal lung infection as it prioritizes limiting cash burn and pursuing strategic...
/PRNewswire/ -- Pulmatrix, Inc. (Nasdaq: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary...
Pulmatrix, Inc. (NASDAQ: PULM) shares dived Thursday, a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and central nervous system disease using its patented dry powder inhalation iSPERSE™ ...
Pulmatrix, Inc. (PULM) announced the FDA has accepted the PUR3100 investigational new drug application and the company has received a study may proceed letter for a phase 2, randomized, double-blind, placebo-controlled, single event study to evaluate PUR3100 in the acute treatment of Migraine.
/PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled...